Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Non-Current Deffered Revenue: 2017-2025

Historic Non-Current Deffered Revenue for Ascendis Pharma A (ASND) over the last 6 years, with Sep 2025 value amounting to $4.9 million.

  • Ascendis Pharma A's Non-Current Deffered Revenue rose 909.57% to $4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.9 million, marking a year-over-year increase of 909.57%. This contributed to the annual value of $5.4 million for FY2024, which is 15.45% down from last year.
  • As of Q3 2025, Ascendis Pharma A's Non-Current Deffered Revenue stood at $4.9 million, which was up 224.35% from -$3.9 million recorded in Q2 2025.
  • Ascendis Pharma A's 5-year Non-Current Deffered Revenue high stood at $14.5 million for Q4 2022, and its period low was -$4.3 million during Q1 2025.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $4.4 million (2023), whereas its average is $2.3 million.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first surged by 31,140.24% in 2022, then slumped by 332.34% in 2025.
  • Ascendis Pharma A's Non-Current Deffered Revenue (Quarterly) stood at $3.4 million in 2021, then skyrocketed by 327.66% to $14.5 million in 2022, then crashed by 55.86% to $6.4 million in 2023, then fell by 16.53% to $5.3 million in 2024, then surged by 909.57% to $4.9 million in 2025.
  • Its Non-Current Deffered Revenue stands at $4.9 million for Q3 2025, versus -$3.9 million for Q2 2025 and -$4.3 million for Q1 2025.